{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:12:16Z","timestamp":1779207136943,"version":"3.51.4"},"reference-count":170,"publisher":"Elsevier","isbn-type":[{"value":"9780443417610","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ircmb.2025.03.001","type":"book-chapter","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:55:48Z","timestamp":1743288948000},"page":"1-46","source":"Crossref","is-referenced-by-count":0,"title":["Cytokine-based immunotherapy in pancreatic cancer"],"prefix":"10.1016","author":[{"given":"Andr\u00e9s","family":"Gordo-Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Ortiz-de-Sol\u00f3rzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.ircmb.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: A comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"European Journal of Medical Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704\u2014A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib15","article-title":"Preoperative interleukin-2 immunotherapy in pancreatic cancer: Preliminary results","volume":"53","author":"Angelini","year":"2006","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.190.7.995","article-title":"An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation","volume":"190","author":"Asseman","year":"1999","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"56968","DOI":"10.18632\/oncotarget.18185","article-title":"Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells","volume":"8","author":"Audenaerde","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2021","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/biomedicines12051065","article-title":"Long-term follow-up of phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for treatment of metastatic pancreatic cancer","volume":"12","author":"Bhatnagar","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4049\/jimmunol.163.4.1809","article-title":"IL-2-independent activation and proliferation in human T cells induced by CD28","volume":"163","author":"Boulougouris","year":"1999","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: From biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejso.2008.12.006","article-title":"Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma","volume":"35","author":"den Broeck","year":"2009","journal-title":"European Journal of Surgical Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib14","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.3390\/cancers14163862","article-title":"A paradoxical role for regulatory T cells in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Brouwer","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229540","article-title":"How can cytokine-induced killer cells overcome CAR-T cell limits","volume":"14","author":"Cappuzzello","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib17","first-page":"1951","article-title":"Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery","volume":"28","author":"Caprotti","year":"2008","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/13543776.2020.1767071","article-title":"Bispecific anti-PD-1\/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: A patent evaluation of US2018326054","volume":"30","author":"Cebada","year":"2020","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib86","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1038689","article-title":"New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer","volume":"4","author":"Chard","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2020.06.011","article-title":"Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)","volume":"490","author":"Chen","year":"2020","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4049\/jimmunol.147.2.528","article-title":"IL-10: A novel cytotoxic T cell differentiation factor","volume":"147","author":"Chen","year":"1991","journal-title":"The Journal of Immunology: Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: A potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib23","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-bethigh foxO1low effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/MPA.0000000000002176","article-title":"Cytokine-induced killer cell immunotherapy combined with gemcitabine reduces systemic metastasis in pancreatic cancer: An analysis using preclinical adjuvant therapy-mimicking pancreatic cancer Xenograft model","volume":"51","author":"Choi","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1126\/science.270.5238.908.a","article-title":"IL-12 deaths: Explanation and a puzzle","volume":"270","author":"Cohen","year":"1995","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib26","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe tumeurs digestives of unicancer, PRODIGE intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Canadian cancer trials group and the unicancer-GI\u2013PRODIGE Group, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib28","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: The master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell\u2013mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib109","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/s41467-022-31130-9","article-title":"Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein","volume":"13","author":"de Picciotto","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib146","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.174.4.915","article-title":"Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression","volume":"174","author":"de Waal Malefyt","year":"1991","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib31","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology\u00a0\/ ESMO"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib32","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.151.3.1224","article-title":"IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression","volume":"151","author":"Ding","year":"1993","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286834","article-title":"A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy","volume":"18","author":"Dower","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166280","article-title":"Interleukins 7 and 15 maintain human T cell proliferative capacity through STAT5 signaling","volume":"11","author":"Drake","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12885-020-06860-y","article-title":"Cytokine-induced killer cell\/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer","volume":"20","author":"Du","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib37","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1038\/s41388-022-02448-x","article-title":"The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma","volume":"41","author":"Evan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib38","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14712598.2013.786697","article-title":"Cetuximab: Still an option in the treatment of pancreatic cancer?","volume":"13","author":"Faloppi","year":"2013","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: One stone, three birds?","volume":"12","author":"Fei","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib41","article-title":"Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers","volume":"13","author":"Feng","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: A systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109816","article-title":"The subunits of IL-12, originating from two distinct cells, can functionally synergize to protect against pathogen dissemination in vivo","volume":"37","author":"Gerber","year":"2021","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib46","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib47","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1189\/jlb.1204723","article-title":"Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control mycobacterium tuberculosis infection","volume":"77","author":"Gonzalez-Juarrero","year":"2005","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib48","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.4049\/jimmunol.1600037","article-title":"IL-12 signals through the TCR To support CD8 innate immune responses","volume":"197","author":"Goplen","year":"2016","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib50","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib51","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1200\/JCO.2018.36.15_suppl.4119","article-title":"Overall survival of PEGylated pegilodecakin with 5-FU\/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC)","volume":"36","author":"Hecht","year":"2018","journal-title":"JCO"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib52","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Hoff","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib56","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102350","article-title":"Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer","volume":"35","author":"Hughson","year":"2024","journal-title":"Molecular Therapy. Nucleic Acids"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib58","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.188.11.2067","article-title":"Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity","volume":"188","author":"Imada","year":"1998","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib59","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib60","first-page":"280","article-title":"Classics in oncology: Virus interference: I. The interferon","volume":"38","author":"Isaacs","year":"1988","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor\u2013secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"JCO"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib62","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.4049\/jimmunol.175.3.1456","article-title":"Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response","volume":"175","author":"Ji","year":"2005","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib126","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: A phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"The Oncologist"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib63","first-page":"693","article-title":"Pancreatic ductal adenocarcinoma: Characteristics of tumor microenvironment and barriers to treatment","volume":"11","author":"Kane","year":"2020","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib64","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/abt\/tbae004","article-title":"Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA","volume":"7","author":"Kim","year":"2024","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1074-7613(01)00167-4","article-title":"The basis for IL-2-induced IL-2 receptor \u03b1 chain gene regulation: Importance of two widely separated IL-2 response elements","volume":"15","author":"Kim","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib66","doi-asserted-by":"crossref","first-page":"40623","DOI":"10.1038\/srep40623","article-title":"Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster","volume":"7","author":"Kim","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib67","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/OTT.S19059","article-title":"Tegafur\/gimeracil\/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: A review comparing it with other fluoropyrimidine-based therapies","volume":"4","author":"Kobayakawa","year":"2011","journal-title":"Onco Targets and Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib70","doi-asserted-by":"crossref","first-page":"2096572","DOI":"10.1080\/2162402X.2022.2096572","article-title":"Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression","volume":"11","author":"Kudling","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib71","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.1997.1176","article-title":"Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis","volume":"180","author":"Kundu","year":"1997","journal-title":"Cellular Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib73","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jss.2009.05.026","article-title":"Significance of M2-polarized tumor-associated macrophage in pancreatic cancer","volume":"167","author":"Kurahara","year":"2011","journal-title":"The Journal of Surgical Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib74","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.4049\/jimmunol.173.3.1731","article-title":"A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1\/2 in human melanoma cells","volume":"173","author":"Kurte","year":"2004","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib75","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib77","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib78","first-page":"382","article-title":"Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib79","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study)","volume":"25","author":"Le","year":"2019","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib80","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201460","article-title":"STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer","volume":"5","author":"Lefler","year":"2022","journal-title":"Life Science Alliance"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib81","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib82","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib43","article-title":"Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells","volume":"35","author":"Lin","year":"2012","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: Anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib83","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/cells8091104","article-title":"Interleukin 21 receptor\/ligand interaction is linked to disease progression in pancreatic cancer","volume":"8","author":"Linnebacher","year":"2019","journal-title":"Cells"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib84","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.ymthe.2021.06.001","article-title":"Bifunctional TGF-\u03b2 trap\/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors","volume":"29","author":"Liu","year":"2021","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib85","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.2147\/IJN.S249174","article-title":"Superior antitumor efficacy of IFN-\u03b12b-Incorporated photo-cross-linked hydrogels combined with T cell transfer and low-dose irradiation against gastric cancer","volume":"15","author":"Liu","year":"2020","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib87","first-page":"2376","article-title":"A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma","volume":"45","author":"Lygidakis","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib88","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/14653249.2011.649185","article-title":"Cytokine-induced killer cells in the treatment of patients with solid carcinomas: A systematic review and pooled analysis","volume":"14","author":"Ma","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib89","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib90","article-title":"A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors","author":"Mamdani","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib91","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.1994.03520170037027","article-title":"Treatment of metastatic melanoma and renal cell carcinoma with interleukin-2","volume":"272","author":"Manson","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib92","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101248","article-title":"Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma","volume":"4","author":"Mascharak","year":"2023","journal-title":"Cell Reports. Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib94","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1078-0432.CCR-16-0004","article-title":"III, IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells","volume":"23","author":"McMichael","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib95","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.13422","article-title":"Low\u2010dose IL\u20102 induces CD56bright NK regulation of T cells via NKp44 and NKp46","volume":"200","author":"McQuaid","year":"2020","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib96","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.celrep.2019.08.095","article-title":"Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment","volume":"29","author":"Mills","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib97","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: Interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib98","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1074-7613(00)80025-4","article-title":"Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells","volume":"10","author":"Moriggl","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib99","doi-asserted-by":"crossref","first-page":"A49","DOI":"10.1016\/S0167-5699(05)80015-5","article-title":"The role of IL-10 in crossregulation of TH1 and TH2 responses","volume":"12","author":"Mosmann","year":"1991","journal-title":"Immunology Today"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib100","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00187","article-title":"The critical role of IL-15\u2013PI3K\u2013mTOR pathway in natural killer cell effector functions","volume":"5","author":"Nandagopal","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","article-title":"IL-10: Master switch from tumor-promoting inflammation to antitumor immunity","volume":"2","author":"Oft","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): A single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib106","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib107","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/biomedicines12040903","article-title":"The role of pretreatment serum interleukin 6 in predicting short-term mortality in patients with advanced pancreatic cancer","volume":"12","author":"Park","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib110","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib111","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cca.2010.09.002","article-title":"IL-7 and lymphopenia","volume":"412","author":"Ponchel","year":"2011","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib112","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/mthe.2002.0570","article-title":"Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a nonimmunogenic tumor model","volume":"5","author":"P\u00fctzer","year":"2002","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib114","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib69","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based Cancer immunotherapy: Challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: Global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World Journal of Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib116","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1541-7786.MCR-17-0784","article-title":"Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGF\u03b2 signaling","volume":"16","author":"Ringuette Goulet","year":"2018","journal-title":"Molecular Cancer Research : MCR"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib117","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib118","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","article-title":"Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes","volume":"89","author":"Rousset","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib121","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/j.1349-7006.2011.02004.x","article-title":"Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination","volume":"102","author":"Sakata","year":"2011","journal-title":"Cancer Science"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib122","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24522","article-title":"IL-21 in cancer immunotherapy: At the right place at the right time","volume":"2","author":"Santegoets","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World Journal of Gastrointestinal Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2013.06.009","article-title":"Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells","volume":"44","author":"Satake","year":"2013","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib125","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.4049\/jimmunol.152.9.4368","article-title":"B7\/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10","volume":"152","author":"Schanden\u00e9","year":"1994","journal-title":"he Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib127","first-page":"153","article-title":"Antitumor activities of IL-12 and mechanisms of action","volume":"68","author":"Shurin","year":"1997","journal-title":"Chemical Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib128","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","article-title":"Interleukin-21 activates human natural killer cells and modulates their surface receptor expression","volume":"123","author":"Skak","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib129","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyae002","article-title":"Signalling mechanisms driving homeostatic and inflammatory effects of interleukin-15 on tissue lymphocytes","volume":"3","author":"Skariah","year":"2024","journal-title":"Discovery Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/antib11030047","article-title":"Antibody-based approaches to target pancreatic tumours","volume":"11","author":"Sorbara","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib131","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: From molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib132","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.imlet.2009.09.009","article-title":"Trans-presentation: A novel mechanism regulating IL-15 delivery and responses","volume":"127","author":"Stonier","year":"2010","journal-title":"Immunology Letters"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib133","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12185-015-1743-y","article-title":"Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed\/refractory multiple myeloma","volume":"101","author":"Suzuki","year":"2015","journal-title":"International Journal of Hematology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib134","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1073\/pnas.161126098","article-title":"IL-7 is critical for homeostatic proliferation and survival of naive T cells","volume":"98","author":"Tan","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/302305a0","article-title":"Structure and expression of a cloned cDNA for human interleukin-2","volume":"302","author":"Taniguchi","year":"1983","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib136","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/0008-5472.CAN-10-4627","article-title":"Interleukin-10 ablation promotes tumor development, growth, and metastasis","volume":"72","author":"Tanikawa","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited: A review of validation studies on tumour assessment","volume":"42","author":"Therasse","year":"2006","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib137","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib138","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.3390\/cancers13164138","article-title":"Pancreatic cancer and immunotherapy: A clinical overview","volume":"13","author":"Timmer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib139","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/212810","article-title":"The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma","volume":"2011","author":"Tjomsland","year":"2011","journal-title":"Clinical & Developmental Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib140","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","article-title":"Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib141","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.4049\/jimmunol.0903151","article-title":"IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis","volume":"184","author":"Unsinger","year":"2010","journal-title":"The Journal of Immunology : Official Journal of the American Association of Immunologists"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112156","article-title":"IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside","volume":"133","author":"Vahidi","year":"2024","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1165","article-title":"Novel combination immunotherapy for pancreatic cancer: Potent anti-tumor effects with CD40 agonist and interleukin-15 treatment","volume":"9","author":"Van Audenaerde","year":"2020","journal-title":"Clinical & Translational Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib143","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-020-02749-8","article-title":"IL-15 superagonist N-803 improves IFN\u03b3 production and killing of leukemia and ovarian cancer cells by CD34+\u2009progenitor-derived NK cells","volume":"70","author":"Van der Meer","year":"2021","journal-title":"Cancer Immunology and Immunotherapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib144","doi-asserted-by":"crossref","first-page":"15373","DOI":"10.1038\/ncomms15373","article-title":"Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells","volume":"8","author":"Vazquez-Lombardi","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib145","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib147","doi-asserted-by":"crossref","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib148","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.3390\/ijms231810412","article-title":"The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy","volume":"23","author":"Wang","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib149","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4049\/jimmunol.162.1.299","article-title":"IL-2 Induces STAT4 Activation in Primary NK Cells and NK Cell Lines, But Not in T Cells1","volume":"162","author":"Wang","year":"1999","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10637-012-9866-y","article-title":"A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma","volume":"31","author":"Wang-Gillam","year":"2013","journal-title":"Investigational New Drugs"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib151","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell\u2013 and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.25449","article-title":"Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras","volume":"128","author":"Wed\u00e9n","year":"2011","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib152","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib153","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s13277-013-1265-2","article-title":"The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma","volume":"35","author":"Wei","year":"2014","journal-title":"Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib154","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib155","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00262-011-1104-5","article-title":"Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3","volume":"60","author":"Wilke","year":"2011","journal-title":"Cancer Immunology, Immunotherapy : CII"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156049","article-title":"IL-7: Comprehensive review","volume":"160","author":"Winer","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib157","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib158","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Molecular Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1242909","article-title":"Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and in vitro experiments","volume":"14","author":"Xu","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI115840","article-title":"The B7\/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro","volume":"90","author":"Young","year":"1992","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib161","first-page":"5678","article-title":"Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy","volume":"14","author":"Yu","year":"2017","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib162","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nature Biomedical Engineering"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib163","first-page":"1","article-title":"Proximity-enabled covalent binding of IL-2 to IL-2R\u03b1 selectively activates regulatory T cells and suppresses autoimmunity","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib164","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108677","article-title":"Development of a recombinant human IL-15\u00b7sIL-15R\u03b1\/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model","volume":"112","author":"Zhao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib166","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s002620050524","article-title":"Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12","volume":"47","author":"Zoll","year":"1998","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.ircmb.2025.03.001_bib167","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1006\/cyto.2000.0733","article-title":"Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation","volume":"12","author":"Zoll","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/bs.ircmb.2025.03.001_fur1","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2025.03.001_fur2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2025.03.001_fur3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncology"}],"container-title":["International Review of Cell and Molecular Biology","Cytokine-based immunotherapy - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193764482500036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193764482500036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:29:45Z","timestamp":1779204585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193764482500036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443417610"],"references-count":170,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2025.03.001","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}